# Convergence Check 53

Timestamp: 2026-05-27 21:00 CEST.

## Forcing Question

Wave97 reopened `CCL20` as the only residual C15ORF48-proximal candidate. Does
that reopening support a `CCL20/CCR6` therapeutic branch?

## Evidence Integrated

- Wave97:
  - `CCL20` was the only `REOPEN_AFTER_RESIDUAL_COSTATE` row.
  - Survival was fragile: residual case-positive in `1` context and `1`
    disease; median residual case r `0.1878`; MS p `0.0611`.
- Wave98 local forcing audit:
  - Passed only the ligand-state recurrence gate.
  - Failed receptor coupling, MS claim-grade anchor, target-resolved genetics,
    perturbation/foundation support, novelty, and host-defense feasibility
    gates.
  - Final call: `NO_GO_CCL20_CCR6_PRIOR_ART_BLOCKED`.
- Wave98 hostile sidecar:
  - `CCL20` is more plausibly an inflammatory chemokine passenger/trafficking
    amplifier than a C15ORF48-controlled mechanism.
  - Minimum promotion tests would require MS spatial/snRNA co-localization,
    residualized replication, C15 perturbation directionality, and selective
    pathogenic Th17 migration effects.
- Wave98 prior-art sidecar:
  - Broad autoimmune `CCL20/CCR6` therapeutic use is novelty-blocked by
    published reviews, EAE/MS/RA/IBD/PsA/AS literature, `GSK3050002` clinical
    development, and patents.
- Wave98 mechanistic sidecar:
  - `CCR6` itself does not share the local C15 co-state.
  - CCL20/CCR6 should be used only as a positive-control trafficking axis.

## Decision

Close `CCL20/CCR6` as a V3 therapeutic nomination.

The useful finding from this branch is negative: ligand-state recurrence can
survive residual co-state testing while the actionable receptor/intervention
axis fails. This prevents another proxy-satisficing error.

## Next Forcing Question

Pivot within the C15 branch to upstream inflammatory stress generators:
`LITAF` and `CASP4`.

Reason:

- Directionality sidecar placed `LITAF` and `CASP4` in the most plausible
  upstream-to-C15 stress-generator class.
- `LITAF` had the strongest donor co-state validation in Wave96 but weak MS and
  no modality.
- `CASP4` has inflammatory-caspase/danger biology but weak MS/genetics and
  selectivity risks.

The next test must be perturbation-first and direction-aware. A raw or
residual co-expression scan alone is insufficient.
